{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:13:47Z","timestamp":1778634827495,"version":"3.51.4"},"reference-count":170,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA248624"],"award-info":[{"award-number":["K08CA248624"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["Z01 BC010891"],"award-info":[{"award-number":["Z01 BC010891"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031272","name":"Eureka Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029611","name":"Association of Schools and Colleges of Optometry","doi-asserted-by":"publisher","award":["K08CA248624"],"award-info":[{"award-number":["K08CA248624"]}],"id":[{"id":"10.13039\/100029611","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpath.2024.10.021","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T21:54:25Z","timestamp":1734126865000},"page":"453-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-5340","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalitya","family":"Andaloori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeha","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-5405","authenticated-orcid":false,"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.10.021_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajpath.2024.10.021_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-015-1475-7","article-title":"Cohort profile: cholangiocarcinoma screening and care program (CASCAP)","volume":"15","author":"Khuntikeo","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.ajpath.2024.10.021_bib5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.dld.2020.06.045","article-title":"Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging","volume":"52","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ajpath.2024.10.021_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visc Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00436-016-5276-y","article-title":"Liver fluke infection and cholangiocarcinoma: a review","volume":"116","author":"Zheng","year":"2017","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ajpath.2024.10.021_bib9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2024.10.021_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.21037\/jgo.2017.03.03","article-title":"Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy","volume":"8","author":"Rogers","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39 Suppl 1","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2024.10.021_bib12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","article-title":"Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin","volume":"57","author":"Dierks","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib16","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7150\/jca.68264","article-title":"The new insight of treatment in cholangiocarcinoma","volume":"13","author":"Li","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/13543784.2021.1897102","article-title":"Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ajpath.2024.10.021_bib19","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib20","doi-asserted-by":"crossref","first-page":"TPS3153","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3153","article-title":"First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced\/metastatic solid tumors","volume":"40","author":"Meric-Bernstam","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib22","first-page":"2838","article-title":"Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice","volume":"58","author":"Shinoda","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1535-7163.MCT-21-0015","article-title":"Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1-positive cholangiocarcinoma","volume":"20","author":"Yokota","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2024.10.021_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib169","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","author":"Uslu","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41434-018-0007-x","article-title":"Driving cars to the clinic for solid tumors","volume":"25","author":"Castellarin","year":"2018","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajpath.2024.10.021_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/bs.acr.2022.01.013","article-title":"Immunotherapy for hepatobiliary cancers: emerging targets and translational advances","volume":"156","author":"Li","year":"2022","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/11595360-000000000-00000","article-title":"Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin","volume":"25","author":"Ho","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ajpath.2024.10.021_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican-3: a new target for cancer immunotherapy","volume":"47","author":"Ho","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7150\/jca.1.141","article-title":"Mesothelin as a potential therapeutic target in human cholangiocarcinoma","volume":"1","author":"Yu","year":"2010","journal-title":"J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.10.021_bib34","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1074\/jbc.270.37.21984","article-title":"Molecular cloning and expression of megakaryocyte potentiating factor cDNA","volume":"270","author":"Kojima","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib35","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2767-9764.CRC-22-0306","article-title":"Structures of cancer antigen mesothelin and its complexes with therapeutic antibodies","volume":"3","author":"Zhan","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep4.1131","article-title":"Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model","volume":"2","author":"Manzanares","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib38","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib39","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3892\/ijo.2012.1662","article-title":"Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer","volume":"41","author":"Kawamata","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3892\/ol.2021.12675","article-title":"Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma","volume":"21","author":"Takihata","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ajpath.2024.10.021_bib41","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.021_bib42","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin SS1P Is modulated by TACE-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib43","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib44","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.021_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/19420862.2017.1289302","article-title":"Humanization of rabbit monoclonal antibodies via grafting combined kabat\/IMGT\/paratome complementarity-determining regions: rationale and examples","volume":"9","author":"Zhang","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ajpath.2024.10.021_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41419-020-2450-z","article-title":"Correction: modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajpath.2024.10.021_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","article-title":"Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor t cells with increased tumor infiltration and persistence for treating solid tumors","volume":"21","author":"Tomar","year":"2022","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.ajpath.2024.10.021_bib48","article-title":"Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.10.021_bib49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.prp.2010.08.004","article-title":"The expression of MUC mucin in cholangiocarcinoma","volume":"206","author":"Mall","year":"2010","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ajpath.2024.10.021_bib50","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.6729450","article-title":"T and Tn, general carcinoma autoantigens","volume":"224","author":"Springer","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.10.021_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib52","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/jcb.26056","article-title":"Dual role of the extracellular domain of human mucin MUC1 in metastasis","volume":"118","author":"Syrkina","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bulcan.2022.08.001","article-title":"MUC1: an emerging target in cancer treatment and diagnosis","volume":"109","author":"Qing","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/imt-2020-0019","article-title":"MUC1 antibody-based therapeutics: the promise of cancer immunotherapy","volume":"12","author":"Pourjafar","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ajpath.2024.10.021_bib55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/vaccines8040659","article-title":"Potential of anti-MUC1 antibodies as a targeted therapy for gastrointestinal cancers","volume":"8","author":"Bose","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ajpath.2024.10.021_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/antib12030047","article-title":"Suppression of MUC1-overexpressing tumors by a novel MUC1\/CD3 bispecific antibody","volume":"12","author":"Fang","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.ajpath.2024.10.021_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0000000000000460","article-title":"Development of engineered CAR T cells targeting tumor-associated glycoforms of MUC1 for the treatment of intrahepatic cholangiocarcinoma","volume":"46","author":"Mao","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.ajpath.2024.10.021_bib58","doi-asserted-by":"crossref","first-page":"16596","DOI":"10.1021\/jacs.8b08473","article-title":"Protective epitope discovery and design of MUC1-based vaccine for effective tumor protections in immunotolerant mice","volume":"140","author":"Wu","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajpath.2024.10.021_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajpath.2024.10.021_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ajpath.2024.10.021_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41419-018-0509-x","article-title":"Role of FGFR2b expression and signaling in keratinocyte differentiation: sequential involvement of PKCdelta and PKCalpha","volume":"9","author":"Rosato","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajpath.2024.10.021_bib62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/cells8070653","article-title":"The aberrant expression of the mesenchymal variant of FGFR2 in the epithelial context inhibits autophagy","volume":"8","author":"Nanni","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.10.021_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ajpath.2024.10.021_bib64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib65","article-title":"A pancancer analysis of the expression landscape and clinical relevance of fibroblast growth factor receptor 2 in human cancers","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib66","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.10.021_bib67","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cytogfr.2019.12.005","article-title":"Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma","volume":"52","author":"Li","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ajpath.2024.10.021_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib70","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4297","article-title":"Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours","volume":"232","author":"Parker","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ajpath.2024.10.021_bib73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.10.021_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41698-021-00220-0","article-title":"Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma","volume":"5","author":"Bitzer","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib75","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.10.021_bib76","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","article-title":"FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib77","first-page":"4508","article-title":"Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification","volume":"11","author":"Kim","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib78","article-title":"Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody","author":"DeDeshpande","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajpath.2024.10.021_bib80","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-10-1489","article-title":"GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling","volume":"70","author":"Bai","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib81","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","article-title":"Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib82","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e15074","article-title":"FPA144, a humanized monoclonal antibody for both amplified and nonamplified overexpressing gastric cancer patients","volume":"32","author":"Pierce","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib83","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.ajpath.2024.10.021_bib85","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib86","doi-asserted-by":"crossref","first-page":"C846","DOI":"10.1152\/ajpcell.00290.2021","article-title":"Role of glypican-1 in regulating multiple cellular signaling pathways","volume":"321","author":"Pan","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib87","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.trecan.2018.09.004","article-title":"Glypicans as cancer therapeutic targets","volume":"4","author":"Li","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib88","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fonc.2019.00614","article-title":"The expression, regulation, and biomarker potential of glypican-1 in cancer","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib89","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1074\/jbc.M111.322487","article-title":"Crystal structure of N-glycosylated human glypican-1 core protein: structure of two loops evolutionarily conserved in vertebrate glypican-1","volume":"287","author":"Svensson","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib90","doi-asserted-by":"crossref","first-page":"22991","DOI":"10.1074\/jbc.M115.660878","article-title":"Structural aspects of N-glycosylations and the C-terminal region in human glypican-1","volume":"290","author":"Awad","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib91","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/onc.2011.430","article-title":"A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis","volume":"31","author":"Whipple","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2024.10.021_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1172\/JCI32412","article-title":"Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells","volume":"118","author":"Aikawa","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.021_bib93","first-page":"5562","article-title":"Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells","volume":"61","author":"Matsuda","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib94","doi-asserted-by":"crossref","first-page":"10816","DOI":"10.1074\/jbc.274.16.10816","article-title":"Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165","volume":"274","author":"Gengrinovitch","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.10.021_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ydbio.2010.09.017","article-title":"Altering glypican-1 levels modulates canonical Wnt signaling during trigeminal placode development","volume":"348","author":"Shiau","year":"2010","journal-title":"Dev Biol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib96","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10620-019-5461-9","article-title":"Glypican-1 promotes tumorigenesis by regulating the PTEN\/Akt\/beta-catenin signaling pathway in esophageal squamous cell carcinoma","volume":"64","author":"Li","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajpath.2024.10.021_bib97","article-title":"GPC1 promotes the growth and migration of colorectal cancer cells through regulating the TGF-beta1\/SMAD2 signaling pathway","volume":"17","author":"Lu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.10.021_bib98","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.2353\/ajpath.2006.050800","article-title":"Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells","volume":"168","author":"Su","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib99","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/modpathol.2017.190","article-title":"Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma","volume":"31","author":"Amatya","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/bjc.2016.183","article-title":"Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma","volume":"115","author":"Hara","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib101","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.7150\/jca.14645","article-title":"Glypican-1 as a biomarker for prostate cancer: isolation and characterization","volume":"7","author":"Truong","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1515\/cclm-2015-0773","article-title":"Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker","volume":"54","author":"Diamandis","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib103","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1002\/cam4.1833","article-title":"High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma","volume":"7","author":"Zhou","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib104","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ijc.31124","article-title":"Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer","volume":"142","author":"Matsuzaki","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib105","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib106","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49392","article-title":"GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab","volume":"9","author":"Kato","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ajpath.2024.10.021_bib107","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves V(H)H-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib108","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1535-7163.MCT-21-0778","article-title":"GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling","volume":"21","author":"Pan","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2024.10.021_bib109","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1186\/s12885-020-07562-1","article-title":"A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells","volume":"20","author":"Lund","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib110","first-page":"120","article-title":"The complexity of targeting EGFR signalling in cancer: from expression to turnover","volume":"1766","author":"Sebastian","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ajpath.2024.10.021_bib111","doi-asserted-by":"crossref","DOI":"10.1590\/0100-6991e-20181826","article-title":"Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival","volume":"45","author":"Gomes","year":"2018","journal-title":"Rev Col Bras Cir"},{"key":"10.1016\/j.ajpath.2024.10.021_bib112","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ajpath.2024.10.021_bib115","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ajpath.2024.10.021_bib116","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib117","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ajpath.2024.10.021_bib118","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.021_bib119","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcyt.2021.05.008","article-title":"Anti-tumor effects of vascular endothelial growth factor\/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells","volume":"23","author":"Xing","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ajpath.2024.10.021_bib120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2353\/ajpath.2007.070152","article-title":"Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule","volume":"171","author":"Trzpis","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib121","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","article-title":"EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma","volume":"68","author":"Yamashita","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jss.2014.05.017","article-title":"Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma","volume":"192","author":"Sulpice","year":"2014","journal-title":"J Surg Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib123","first-page":"2355","article-title":"Construction of chimeric antigen receptor-modified T cells targeting EpCAM and assessment of their anti-tumor effect on cancer cells","volume":"20","author":"Zhou","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ajpath.2024.10.021_bib124","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1292\/jvms.20-0455","article-title":"Chimeric antigen receptor-T (CAR-T) cells targeting epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model","volume":"83","author":"Fu","year":"2021","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.ajpath.2024.10.021_bib125","doi-asserted-by":"crossref","first-page":"24644","DOI":"10.18632\/oncotarget.15602","article-title":"PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma","volume":"8","author":"Fontugne","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2024.10.021_bib126","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/ol.2017.6105","article-title":"PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma","volume":"14","author":"Ma","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ajpath.2024.10.021_bib127","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib128","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib129","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.021_bib130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.omto.2022.02.015","article-title":"A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ajpath.2024.10.021_bib131","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib132","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ajpath.2024.10.021_bib133","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib134","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajpath.2024.10.021_bib136","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrc.2017.74","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib137","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib138","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib139","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2024.10.021_bib141","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib142","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib143","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib144","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156211","article-title":"Messenger RNA vaccines for cancer immunotherapy: progress promotes promise","volume":"132","author":"Huff","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.021_bib146","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2024.10.021_bib147","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122857","article-title":"Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer","volume":"3","author":"Kinkead","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajpath.2024.10.021_bib148","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1172\/JCI120775","article-title":"Emerging strategies for combination checkpoint modulators in cancer immunotherapy","volume":"128","author":"Popovic","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.021_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004892","article-title":"Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities","volume":"10","author":"Lin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib150","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.10.021_bib151","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc3947","article-title":"The emerging complexity of gene fusions in cancer","volume":"15","author":"Mertens","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib152","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.10.021_bib153","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.021_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2004.10.022","article-title":"Function of alternative splicing","volume":"344","author":"Stamm","year":"2005","journal-title":"Gene"},{"key":"10.1016\/j.ajpath.2024.10.021_bib155","first-page":"147","article-title":"Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma","volume":"10","author":"Yosudjai","year":"2019","journal-title":"Biomed Rep"},{"key":"10.1016\/j.ajpath.2024.10.021_bib156","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/cas.12967","article-title":"CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment","volume":"107","author":"Thanee","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajpath.2024.10.021_bib170","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/2767-9764.CRC-23-0309","article-title":"SpliceMutr enables pan-cancer analysis of splicing-derived neoantigen burden in tumors","volume":"4","author":"Palmer","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ajpath.2024.10.021_bib157","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/biomedicines11030936","article-title":"HERVs and cancer: a comprehensive review of the relationship of human endogenous retroviruses and human cancers","volume":"11","author":"Stricker","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajpath.2024.10.021_bib158","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Luksza","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.021_bib159","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdy413","article-title":"Human endogenous retroviruses and their implication for immunotherapeutics of cancer","volume":"29","author":"Attermann","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib160","first-page":"13246","article-title":"Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy","volume":"13","author":"Sarantis","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ajpath.2024.10.021_bib161","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc.2017.35","article-title":"Transposable elements in cancer","volume":"17","author":"Burns","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib162","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12885-017-3595-8","article-title":"Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma","volume":"17","author":"Jeong","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2024.10.021_bib163","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.10.021_bib164","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib165","first-page":"1573","article-title":"An advanced intrahepatic cholangiocarcinoma patient benefits from personalized immunotherapy","author":"Zhu","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.ajpath.2024.10.021_bib166","article-title":"Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib167","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrgastro.2011.222","article-title":"The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma","volume":"9","author":"Sirica","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.021_bib168","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.acr.2020.10.005","article-title":"Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression","volume":"149","author":"Sirica","year":"2021","journal-title":"Adv Cancer Res"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:48:20Z","timestamp":1778633300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024004425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002944024004425"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.021","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}